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Do patients have the right to medicate themselves, or should they be punished for doing so? Should 
their own doctors work with them to decide on the best treatment, or does the government know 
best? These questions are at the heart of the current debate on the use of cannabis as medicine.  
 
/ŶƚŚĞh< ? ‘Đannabis-based products for medical use ŝŶŚƵŵĂŶƐ ?were rescheduled on 1st November 
2018. They were placed in schedule 2 of the Misuse of Drugs Regulations, alongside several opioid 
analgesics. In theory, this means they can now be prescribed. In practice, the NHS has warned that 
 ‘ǀĞƌǇĨĞǁƉĞŽƉůĞŝŶŶŐůĂŶĚĂƌĞůŝŬĞůǇƚŽŐĞƚĂƉƌĞƐĐƌŝƉƚŝŽŶĨŽƌŵĞĚŝĐĂůĐĂŶŶĂďŝƐ ?,1 due to the tight 
restrictions that have been put in place.2,3  
 
Under the Misuse of Drugs Act, people face criminal prosecution for possession without a 
prescription of substances in schedule 2. According to some ethical arguments, this breaches their 
right to decide autonomously on their own wellbeing.4 As patients have the right to refuse 
treatment under the doctrine of informed consent, they also  ? it is argued  ? have the right to decide 
on the treatments they want to use.  
 
In the case of cannabis, there is evidence of patient benefit for a wide range of conditions, including 
chronic pain, chemotherapy-induced nausea, some forms of epilepsy, multiple sclerosis spasticity, 
ƐůĞĞƉĚŝƐŽƌĚĞƌƐ ?ǁĞŝŐŚƚůŽƐƐŽƌŐĂŝŶĂƐƐŽĐŝĂƚĞĚǁŝƚŚ,/s ?dŽƵƌĞƚƚĞ ?ƐƐǇŶĚƌŽŵĞ ?ĂŶǆŝĞƚǇĚŝƐŽƌĚĞƌ ?and 
post-traumatic stress disorder.5 ?8 Some patients with other conditions - including glaucoma9 and 
inflammatory bowel disease10 - also report benefits. There is pre-clinical evidence that cannabis-
based medicines may have a role in combating some forms of cancer.11,12 The evidence of benefits is 
much weaker for some conditions than for others, but is there a good reason why patients should 
receive punishment and a criminal record for seeking them out? 
 
The argument to maintain tight control of prescription is based on fear of the potential 
consequences of a more liberal approach.13 Patient safety is an important concern. There are 
general risks associated with use of cannabis. These include cardiovascular and mental health 
problems, as well as dependence.6,8 There are also condition-specific risks. For example, cannabis 
use may reduce blood pressure, so it may cause particular harms to people with glaucoma.9 This 
paternalist concern can be mitigated by ensuring that patients have access to accurate information 
on both harms and benefits of cannabis. They can then decide for themselves whether they wish to 
run these risks. 
 
Another concern is that cannabis will be diverted from medical use to fuel the black market for 
recreational use. This fear was raised by 166 pain specialists in a recent letter to the Times.14  They 
argued that prescribing cannabis may cause problems similar to an opioid crisis. These fears are 
overblown, and not just because cannabis is far less lethal than opioids.15 Legalising medical 
marijuana, with relatively liberal access, has not caused major increases in cannabis use in the USA.16 
Indeed, there are some indications that it has reduced harms associated with opioid analgesics, 
including overdose, workplace and traffic fatalities.17 ?19  
 
The potential demand for medical cannabis in the UK is large. Thirteen per cent of respondents to a 
ƌĞĐĞŶƚŽƉŝŶŝŽŶƉŽůů ‘would actively ask their doctor or healthcare provider about accessing cannabis 
ŵĞĚŝĐŝŶĞƐ ? ?20 The NHS, however, aims to limit prescriptions to children with rare forms of epilepsy 
and patients with chemotherapy-induced nausea, and only after other treatments fail.1 The 
predictable consequence is that many patients will continue to get cannabis from the illegal market, 
as they have done under AustralŝĂ ?ƐƐŝŵŝůĂƌůǇƌĞƐƚƌŝĐƚŝǀĞregime.21 So they will continue to fund the 
harms of organised crime, to use products of uncertain content, quality and consistency, and to be 
treated as criminals for seeking to relieve their suffering. 
 
dŚĞh< ?s new system prevents patients who may benefit from accessing cannabis legally. It also 
severely limits the ability of their own doctors to prescribe it. It leaves cannabinoids that are not 
prepared as medicines for human use in the most restrictive schedule 1, so it continues to limit 
access for clinical research. The right regulations for drugs are both an ethical and an empirical issue. 
The ethical questions hinge on the actual effects of different approaches.22 So we need to invest in 
research on policy, as well as on the clinical aspects of cannabis.23  
 
In the short-term, we should relax restrictions on prescription and reduce the harms of 
criminalisation by moving all plant-based cannabis products to schedule 4 (ii), alongside anabolic 
steroids. As for steroids, people should not be prosecuted for possessing cannabis for their own 
personal use.  In the longer term, we will need to consider more ethical and effective ways to 
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